Sigilon Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Sigilon Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q2 2023.
  • Sigilon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $1.56M, a 9.94% decline year-over-year.
  • Sigilon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $5.46M, a 6.01% decline year-over-year.
  • Sigilon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5.9M, a 4.05% decline from 2021.
  • Sigilon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $6.15M, a 96.7% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $5.46M $1.56M -$172K -9.94% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $5.63M $1.35M -$269K -16.6% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $5.9M $1.21M +$255K +26.7% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-14
Q3 2022 $5.65M $1.34M -$163K -10.8% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $5.81M $1.73M -$255K -12.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $6.06M $1.62M -$86K -5.05% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $6.15M $955K -$75K -7.28% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 $6.23M $1.51M +$771K +105% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $5.45M $1.99M +$1.29M +185% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $4.16M $1.7M +$1.04M +155% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $3.13M $1.03M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 $734K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $696K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $667K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.